Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats

Neuropharmacology

Volumn 46, Issue 7, 2004, Pages 954-965

  Morley, Kirsten C ^a   Li, Kong M ^b   Hunt, Glenn E ^a   Mallet, Paul E ^c   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

Cannabinoid; Ecstasy; Hyperthermia; Hypothermia; MDMA; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 HYDROXYINDOLEACETIC ACID; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; RIMONABANT; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPERACTIVITY; HYPERTHERMIA; INDUCED HYPOTHERMIA; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SOCIAL INTERACTION; TASK PERFORMANCE;

ANIMALS; CANNABINOIDS; CYCLOHEXANOLS; FEVER; MALE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SEROTONIN;

EID: 1842664351     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.01.002     Document Type: Article

References (46)

1. Arnold J.C., Topple A.N., Hunt G.E., McGregor I.S. Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. European Journal of Pharmacology. 354:1998;9-16.
2. Arnold J.C., Topple A.N., Mallet P.E., Hunt G.E., McGregor I.S. The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research. 921:2001;240-255.
3. Boot B.P., McGregor I.S., Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet. 355:2000;1818-1821.
4. Boys A., Lenton S., Norcross K. Polydrug use at raves by a Western Australian sample. Drug and Alcohol Review. 16:1997;227-234.
5. Bull E.J., Hutson P.H., Fone K.C.F. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT(2C) receptor responsivity. Neuropharmacology. 44:2003;439-448.
6. Chen Y., Buck J. Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. Journal of Experimental Therapeutics. 293:2000;807-812.
7. Colado M.I., Green A.R. The spin trap reagent alpha-phenyl-n-tert-butyl nitrone prevents Ecstasy-induced neurodegeneration of 5-hydroxytryptamine neurones. European Journal of Pharmacology. 280:1995;343-346.
8. Colado M.I., O'Shea E., Granados R., Murray T.K., Green A.R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('Ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. British Journal of Pharmacology. 121:1997;889-900.
9. Colado M.I., Granados R., Oshea E., Esteban B., Green A.R. Role of hyperthermia in the protective action of clomethiazole against MDMA ('Ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896AR. British Journal of Pharmacology. 124:1998;479-484.
10. Colado M.I., O'Shea E., Esteban B., Green A.R. Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ("Ecstasy")-induced neurodegeneration in rat brain. Psychopharmacology. 157:2001;82-88.
11. Cole J.C., Sumnall H.R., Grob C. Sorted: Ecstasy facts and fiction. The Psychologist. 15:2002;464-467.
12. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. Journal of Pharmacology and Experimental Therapeutics. 277:1996;586-594.
13. Croft R.J., Mackay A.J., Mills A.T.D., Gruzelier J.G.H. The relative contributions of Ecstasy and cannabis to cognitive impairment. Psychopharmacology. 153:2001;373-379.
14. Fennessy M.R., Taylor D.A. Antagonism of the effects on thermoregulation of delta9-tetrahydrocannabinol by clomipramine in the rat. British Journal of Pharmacology. 63:1978;267-273.
15. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. Journal of Neuroscience Methods. 2:1980;219-238.
16. Fone K.C.F., Beckett S.R.G., Topham I.A., Swettenham J., Ball M., Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology. 159:2002;437-444.
17. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacological Reviews. 55:2003;463-508.
18. Gurtman C.G., Morley K.C., Li K.M., Hunt G.E., McGregor I.S. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"): association with serotonin depletion. European Journal of Pharmacology. 446:2002;89-96.
19. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)delta(9)-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;8268-8273.
20. Leker R.R., Shohami E., Abramsky O., Ovadia H. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. Journal of the Neurological Sciences. 162:1999;114-119.
21. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. Journal of Neuroscience. 18:1998;5086-5094.
22. Malberg J.E., Sabol K.E., Seiden L.S. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. Journal of Pharmacology and Experimental Therapeutics. 278:1996;258-267.
23. Malone D.T., Taylor D.A. Modulation of delta(9)-tetrahydrocannabinol- induced hypothermia by fluoxetine in the rat. British Journal of Pharmacology. 124:1998;1419-1424.
24. Malone D.T., Taylor D.A. Involvement of somatodendritic 5-HT1A receptors in delta(9)-tetrahydrocannabinol-induced hypothermia in the rat. Pharmacology, Biochemistry and Behavior. 69:2001;595-601.
25. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. Journal of Neurochemistry. 80:2002;448-456.
26. Martinez-Orgado J., Fernandez-Frutos B., Gonzales R., Romero E., Uriguen L., Romero J., Viveros M.P. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Molecular Brain Research. 114:2003;132-139.
27. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
28. McGregor I.S., Clemens K.J., Van Der Plasse G., Li K.M., Hunt G.E., Lawrence A.J. Increased anxiety 3 months after brief exposure to MDMA ('Ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology. 28:2003a;1472-1484.
29. McGregor I.S., Gurtman C.G., Morley K.C., Clemens K.J., Blockland A., Li K.M., Cornish J.L., Hunt G.E. Increased anxiety and "depressive" symptoms months after MDMA ("Ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology. 168:2003b;465-474.
30. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology. 152:2000;230-248.
31. Morley K.C., McGregor I.S. (+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. European Journal of Pharmacology. 408:2000;41-49.
32. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., McGregor I.S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("Ecstasy"). European Journal of Pharmacology. 433:2001;91-99.
33. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K.L., Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. Journal of Neuroscience. 19:1999;2987-2995.
34. Norwood C.S., Cornish J.L., Mallet P.E., McGregor I.S. Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. European Journal of Pharmacology. 465:2003;105-114.
35. O'Shea E., Granados R., Esteban B., Colado M.I., Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (Ecstasy). Neuropharmacology. 37:1998;919-926.
36. O'Shea E., Esteban B., Camarero J., Green A.R., Colado M.I. Effect of GBR12909 and fluoxetine on the acute and long term changes induced by MDMA ('Ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology. 40:2001;65-74.
37. Parrott A.C. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology. 16:2001;557-577.
38. Pryor G.T., Larsen F.F., Husain S., Braude M.C. Interactions of delta9-tetrahydrocannabinol with D-amphetamine, cocaine, and nicotine in rats. Pharmacology, Biochemistry and Behavior. 8:1978;295-318.
39. Reneman L., Booij J., de Bruin K., Reitsma J.B., de Wolff F.A., Gunning W.B., den Heeten G.L., van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (Ecstasy) on brain serotonin neurons. Lancet. 358:2001;1864-1869.
40. Ricaurte G.A., McCann U.D., Szabo Z., Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicology Letters. 112:2000;143-146.
41. Shankaran M., Yamamoto B.K., Gudelsky G.A. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse. 40:2001;55-64.
42. Shohami E., Mechoulam R. Dexanabinol (HU-211): a nonpsychotropic cannabinoid with neuroprotective properties. Drug Development Research. 50:2000;211-215.
43. Siliquini R., Faggiano F., Geninatti S., Versino E., Mitola B., Ippolito R. Patterns of drug use among young men in Piedmont (Italy). Drug and Alcohol Dependence. 64:2001;329-335.
44. Thompson, M., Li, K.M., Clemens, K.C., Cornish, J.L., Hunt, G.E., McGregor, I.S., 2003. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ("Ecstasy") in rats. Neuropsychopharmacology. Available on-line at www.nature.com/npp from 12 November 2003.
45. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug and Alcohol Dependence. 55:1999;105-115.
46. Winstock A.R., Griffiths P., Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug and Alcohol Dependence. 64:2001;9-17.